Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Chan Hyuk | - |
dc.contributor.author | Kim, Hyun-Soo | - |
dc.contributor.author | Lee, Sang Kil | - |
dc.date.accessioned | 2022-07-16T04:06:02Z | - |
dc.date.available | 2022-07-16T04:06:02Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159629 | - |
dc.description.abstract | Background/Aims DA-9701 (Motilitone) is a new prokinetic agent formulated with Corydalis Tuber and Pharbitis Seed. We assessed the efficacy of DA-9701 in symptomatic patients with minimal change esophagitis. Methods Patients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive either DA-9701 30 mg or placebo t.i.d. (means 3 times a day). After 4 weeks of treatment, the primary efficacy end point determined by changes of the Nepean dyspepsia index questionnaire-Korean version (NDI-K) symptom scores, was analyzed. Results Forty-two and 39 patients were assigned to the treatment and control groups, respectively. After 4 weeks, NDI-K symptom scores were reduced from 35.4 to 13.5 (P < 0.001) and from 43.0 to 27.7 (P < 0.001) in the treatment and the control groups, respectively. However, changes in the symptom scores did not differ between the 2 groups (P = 0.741). Although the quality of life scores were significantly improved after 4 weeks in both groups, changes in the quality of life score between the baseline value and that at 4 weeks did not differ between the 2 groups. The reflux symptom score was significantly improved in the treatment group compared to the placebo group in patients aged 65 years or older (P = 0.035). Conclusions Although NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores compared with the placebo. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY | - |
dc.title | Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Chan Hyuk | - |
dc.identifier.doi | 10.5056/jnm14019 | - |
dc.identifier.scopusid | 2-s2.0-84903961555 | - |
dc.identifier.wosid | 000338614700007 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, v.20, no.3, pp.338 - 346 | - |
dc.relation.isPartOf | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.title | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 338 | - |
dc.citation.endPage | 346 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001898261 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | GASTROESOPHAGEAL-REFLUX DISEASE | - |
dc.subject.keywordPlus | FUNCTIONAL DYSPEPSIA | - |
dc.subject.keywordPlus | MOTOR FUNCTION | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | HEARTBURN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | RABEPRAZOLE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | DA-9701 | - |
dc.subject.keywordAuthor | Minimal change esophagitis | - |
dc.subject.keywordAuthor | Motilitone | - |
dc.subject.keywordAuthor | Non-erosive reflux disease | - |
dc.identifier.url | https://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm14019 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.